Patent · US Active

Anti-IGF antibodies

US8580254B2 · kind B2 · utility

27Cited by

12References

17Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Paul Adam · Wien, AT
Elinborg Ostermann · Mauerbach, AT

Key dates

Filing date	Jun 19, 2008
Grant date	Nov 12, 2013
Priority date	—
Expiry date	Apr 20, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.